Gracell Bioscience

Gracell Biotechnologies is a clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary technology platforms, FasTCAR and TruUCAR, to overcome industry challenges such as long manufacturing times, high production costs, and limited efficacy of conventional CAR-T therapies. Its lead candidate, GC012F, is a dual-targeting BCMA/CD19 CAR-T therapy currently being evaluated for multiple myeloma and systemic lupus erythematosus. In early 2024, Gracell was acquired by AstraZeneca, significantly bolstering AstraZeneca's cell therapy pipeline and manufacturing capabilities. The company maintains a strong presence in both China and the United States, focusing on next-generation autologous and allogeneic cell therapy solutions.